Nord/LB set a €74.40 ($88.57) price target on STADA Arzneimittel (ETR:SAZ) in a research report sent to investors on Wednesday, December 20th. The firm currently has a sell rating on the stock.
A number of other research firms have also weighed in on SAZ. Warburg Research set a €74.40 ($88.57) price target on shares of STADA Arzneimittel and gave the stock a sell rating in a research report on Wednesday, December 20th. Independent Research set a €89.00 ($105.95) price target on shares of STADA Arzneimittel and gave the stock a neutral rating in a research report on Wednesday, December 20th. Commerzbank set a €66.25 ($78.87) price target on shares of STADA Arzneimittel and gave the stock a sell rating in a research report on Wednesday, December 20th. Finally, S&P Global set a €74.40 ($88.57) price target on shares of STADA Arzneimittel and gave the stock a sell rating in a research report on Friday, November 10th. Four analysts have rated the stock with a sell rating and two have assigned a hold rating to the stock. The stock presently has an average rating of Sell and an average target price of €74.08 ($88.18).
Shares of STADA Arzneimittel (ETR SAZ) traded down €0.08 ($0.10) during midday trading on Wednesday, reaching €88.58 ($105.45). 37,896 shares of the company traded hands, compared to its average volume of 55,841. The company has a market capitalization of $5,520.00 and a price-to-earnings ratio of 58.28. STADA Arzneimittel has a 12 month low of €46.31 ($55.13) and a 12 month high of €89.76 ($106.86).
ILLEGAL ACTIVITY WARNING: This piece was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/13/stada-arzneimittel-saz-given-a-74-40-price-target-by-nordlb-analysts.html.
About STADA Arzneimittel
STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidine naloxone for pain; Atorvastatin for elevated cholesterol levels; Pantoprazole for stomach ulcer/reflux; Diclofenac for pain/inflammation; and Enalapril for high blood pressure indications.
Receive News & Ratings for STADA Arzneimittel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STADA Arzneimittel and related companies with MarketBeat.com's FREE daily email newsletter.